Managing patients with 'statin intolerance': A retrospective study

British Journal of Cardiology

Volumn 15, Issue 3, 2008, Pages 158-160

  Nair, Rajesh K ^a   Karadi, Rangaprasad L ^a   Kilpatrick, Eric S ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Alternative therapy; Metabolism; Side effects; Statins; Tolerance

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ALOPECIA; ARTICLE; BLISTER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SUBSTITUTION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; MALE; MUSCLE DISEASE; MYALGIA; OUTPATIENT DEPARTMENT; PATIENT IDENTIFICATION; RETROSPECTIVE STUDY; SIDE EFFECT;

EID: 45849121731     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. National Institute for Health and Clinical Excellence. Cardiovascular disease - statins. London: NICE, 2006. Available from: http://www.nice.org.uk/guidance/TA94 [accessed 18th December 2006].
2. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164:208-11.
3. Moghadasian MH. A safety look at currently available statins. Expert Opin Drug Saf 2002;1:269-74.
4. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
5. De Angelis G. The influence of statin characteristics on their safety and tolerability. Int J Clin Pract 2004;58:945-55.